Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.
2019
9090Background: The clinicopathologic characteristics and optimal treatment strategies for non-sensitizing EGFR (ns-EGFR) and HER2 activating mutations in NSCLC remain unclear. Methods: Single-cent...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI